Carregant...
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Bispecific antibodies have moved from being an academic curiosity with therapeutic promise to reality, with two molecules being currently commercialized (Hemlibra(®) and Blincyto(®)) and many more in clinical trials. The success of bispecific antibodies is mainly due to the continuously growing numb...
Guardat en:
| Publicat a: | BioDrugs |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6182456/ https://ncbi.nlm.nih.gov/pubmed/30132211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-018-0299-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|